by Sam Eskandari | Jun 6, 2017 | News
June 6, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), as an ACMPR applicant would like to notify its investors that Health Canada is introducing several improvements that aim to streamline the ACMPR licensing process....
by Sam Eskandari | May 30, 2017 | News
May 30, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) is pleased to announce that Cannevert Therapeutic Ltd.’s development of its medicinal cannabis pipeline has expanded to include anti-emesis (anti-nausea/vomiting) therapies....
by Sam Eskandari | May 17, 2017 | News
May 17, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce the appointment of David Greenway as a Director of the Company. Mr. Greenway has two decades of...
by Sam Eskandari | May 8, 2017 | News
May 8, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that its research arm, Cannevert Therapeutics Ltd. is moving swiftly towards properly certified and...
by Lui Franciosi | Apr 21, 2017 | News
April 21, 2017, Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) announces that, further to its December 21, 2015 and October 5, 2016 news releases, it has paid the final installment for its acquisition of 80%...
by Lui Franciosi | Apr 18, 2017 | News
April 18, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that CEO and President, Dr. Lui Franciosi will present at The Planet Microcap Showcase 2017...
by Sam Eskandari | Mar 14, 2017 | News
March 15, 2017, Vancouver, B.C. – Veritas Pharma Inc. “Veritas” (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that it has entered into an agreement with AlphaPheno Inc....
by Sam Eskandari | Mar 13, 2017 | News
March 13, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that its research arm, Cannevert Therapeutics Ltd, will soon be entering the security inspection...
by Sam Eskandari | Mar 11, 2017 | News
March 10, 2017, Vancouver, B.C. Veritas Pharma Inc. “Veritas” , (trading on: CSE: VRT – OTC: VRTHF – FSE: 2VP), has provided updates on its agreement, accomplishments and closing terms for the acquisition of Cannevert Therapeutics Ltd. CTL is...
by Sam Eskandari | Mar 5, 2017 | News
March 5, 2017, Vancouver, B.C. Veritas Pharma Inc. “Veritas” , (trading on: CSE: VRT – OTC: VRTHF – FSE: 2VP), pursuant to the news release dated February 20, 2017, was notified by Health Canada to be in the final review stage of its license...
